Bypassing the bloodâbrian barrier using established skull base reconstruction techniques

Background: Neurological disorders represent a profound healthcare problem accounting for 6.3% of the global disease burden. Alzheimer's disease alone is expected to impact over 115 million people worldwide by 2050 with a cost of over $1 trillion per year to the U.S. economy. Despite considerab...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marcel M. Miyake, Benjamin S. Bleier
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2015
Materias:	Otorhinolaryngology RF1-547 Surgery RD1-811
Acceso en línea:	https://doaj.org/article/e1edf02f9c16426b991b1e136fe2d778
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e1edf02f9c16426b991b1e136fe2d778
record_format	dspace
spelling	oai:doaj.org-article:e1edf02f9c16426b991b1e136fe2d7782021-12-02T12:05:00ZBypassing the bloodâbrian barrier using established skull base reconstruction techniques2095-881110.1016/j.wjorl.2015.09.001https://doaj.org/article/e1edf02f9c16426b991b1e136fe2d7782015-09-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095881115300123https://doaj.org/toc/2095-8811Background: Neurological disorders represent a profound healthcare problem accounting for 6.3% of the global disease burden. Alzheimer's disease alone is expected to impact over 115 million people worldwide by 2050 with a cost of over $1 trillion per year to the U.S. economy. Despite considerable advances in our understanding of the pathogenesis and natural history of neurological disorders, the development of disease modifying therapies have failed to keep pace. This lack of effective treatments is directly attributable to the presence of the bloodâbrain and bloodâcerebrospinal fluid barriers (BBB and BCSFB) which prevent up to 98% of all potential neuropharmaceutical agents from reaching the central nervous system (CNS). These obstacles have thereby severely limited research and development into novel therapeutic strategies for neurological disease. Current experimental methods to bypass the BBB, including pharmacologic modification and direct transcranial catheter implantation, are expensive, are associated with significant complications, and cannot be feasibly scaled up to meet the chronic needs of a large, aging patient population. Transmucosal drug delivery: An innovative method of direct CNS drug delivery using heterotopic mucosal grafts was described. This method is based on established endoscopic skull base nasoseptal flap reconstruction techniques. The model has successfully demonstrated CNS delivery of chromophore-tagged molecules 1000 times larger than those typically permitted by the BBB. Conclusions: This innovative technique represents the first described method of permanently bypassing the bloodâbrain barrier using purely autologous tissues. This has the potential to dramatically improve the current treatment of neurological disease by providing a safe and chronic transnasaldelivery pathway for high molecular weight neuropharmaceuticals. Keywords: Bloodâbrain barrier, Transnasal drug delivery, Skull base reconstruction, Mucosal flapMarcel M. MiyakeBenjamin S. BleierKeAi Communications Co., Ltd.articleOtorhinolaryngologyRF1-547SurgeryRD1-811ENWorld Journal of Otorhinolaryngology-Head and Neck Surgery, Vol 1, Iss 1, Pp 11-16 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Otorhinolaryngology RF1-547 Surgery RD1-811
spellingShingle	Otorhinolaryngology RF1-547 Surgery RD1-811 Marcel M. Miyake Benjamin S. Bleier Bypassing the bloodâbrian barrier using established skull base reconstruction techniques
description	Background: Neurological disorders represent a profound healthcare problem accounting for 6.3% of the global disease burden. Alzheimer's disease alone is expected to impact over 115 million people worldwide by 2050 with a cost of over $1 trillion per year to the U.S. economy. Despite considerable advances in our understanding of the pathogenesis and natural history of neurological disorders, the development of disease modifying therapies have failed to keep pace. This lack of effective treatments is directly attributable to the presence of the bloodâbrain and bloodâcerebrospinal fluid barriers (BBB and BCSFB) which prevent up to 98% of all potential neuropharmaceutical agents from reaching the central nervous system (CNS). These obstacles have thereby severely limited research and development into novel therapeutic strategies for neurological disease. Current experimental methods to bypass the BBB, including pharmacologic modification and direct transcranial catheter implantation, are expensive, are associated with significant complications, and cannot be feasibly scaled up to meet the chronic needs of a large, aging patient population. Transmucosal drug delivery: An innovative method of direct CNS drug delivery using heterotopic mucosal grafts was described. This method is based on established endoscopic skull base nasoseptal flap reconstruction techniques. The model has successfully demonstrated CNS delivery of chromophore-tagged molecules 1000 times larger than those typically permitted by the BBB. Conclusions: This innovative technique represents the first described method of permanently bypassing the bloodâbrain barrier using purely autologous tissues. This has the potential to dramatically improve the current treatment of neurological disease by providing a safe and chronic transnasaldelivery pathway for high molecular weight neuropharmaceuticals. Keywords: Bloodâbrain barrier, Transnasal drug delivery, Skull base reconstruction, Mucosal flap
format	article
author	Marcel M. Miyake Benjamin S. Bleier
author_facet	Marcel M. Miyake Benjamin S. Bleier
author_sort	Marcel M. Miyake
title	Bypassing the bloodâbrian barrier using established skull base reconstruction techniques
title_short	Bypassing the bloodâbrian barrier using established skull base reconstruction techniques
title_full	Bypassing the bloodâbrian barrier using established skull base reconstruction techniques
title_fullStr	Bypassing the bloodâbrian barrier using established skull base reconstruction techniques
title_full_unstemmed	Bypassing the bloodâbrian barrier using established skull base reconstruction techniques
title_sort	bypassing the bloodâbrian barrier using established skull base reconstruction techniques
publisher	KeAi Communications Co., Ltd.
publishDate	2015
url	https://doaj.org/article/e1edf02f9c16426b991b1e136fe2d778
work_keys_str_mv	AT marcelmmiyake bypassingthebloodabrianbarrierusingestablishedskullbasereconstructiontechniques AT benjaminsbleier bypassingthebloodabrianbarrierusingestablishedskullbasereconstructiontechniques
_version_	1718394721964916736

Bypassing the bloodâbrian barrier using established skull base reconstruction techniques

Ejemplares similares